Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study

Jorge Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C. Heinrich, Timothy P Hughes, Jeroen J.W.M. Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J. DeAngelo, Gessami Sanchez-Olle, Nathalie Pognan, Jomy Jose, Matthias Hoch, Michael Mauro

Blood (2023) 142 (Supplement 1): 868.

https://doi.org/10.1182/blood-2023-189270

Published: 2023

Journal Articles

Preclinical Evaluation of the Efficacy of Human Sirpα Antibodies for B-Cell Lymphoma Immunotherapy in Humanized Mouse Models

Yasuyuki Saito, Afroj Tania, Satomi Komori, Tomoko Takai, Okechi S Oduori, Takenori Kotani, Yohei Funakoshi, Yoji Murata, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami, Markus G. Manz, Takashi Matozaki

Blood (2023) 142 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2023-181926

Published: 2023

Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Blood (2023) 142 (Supplement 1): 450.

https://doi.org/10.1182/blood-2023-187322

Published: 2023

Journal Articles

Routinely Calculable Biomarkers Are Associated with the Development of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation

Hiroya Ichikawa, Kimikazu Yakushijin, Takahiro Tsuji, Naoko Takemoto, Miki Joyce, Yuri Okazoe, Ruri Takahashi, Sakuya Matsumoto, Rina Sakai, Keiji Kurata, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami

Blood (2023) 142 (Supplement 1): 2157.

https://doi.org/10.1182/blood-2023-185215

Published: 2023

Journal Articles

Global Longitudinal Strain Is Superior to Ejection Fraction for Long-Term Follow-up after Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 1824.

https://doi.org/10.1182/blood-2021-150449

Published: 2021

Journal Articles

Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody

Blood (2021) 138 (Supplement 1): 534.

https://doi.org/10.1182/blood-2021-148981

Published: 2021

Journal Articles

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Yukio Kobayashi, Iekuni Oh, MD PhD, Toshihiro Miyamoto, MD PhD, Won-Sik Lee, Hiroatsu Iida, MD PhD, Hironobu Minami, MD PhD, Yoshinobu Maeda, MD PhD, Jun Ho Jang, Sung-Soo Yoon, MD PhD, Su-Peng Yeh, MD, Qui Tran, Joan Morris, Janet L. Franklin, Ka-Wing Chong, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 5069.

https://doi.org/10.1182/blood-2019-124582

Published: 2019

Journal Articles

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Yukio Kobayashi, MD DSc, Zachary F. Zimmerman, Iekuni Oh, MD PhD, Yoshinobu Maeda, MD PhD, Hironobu Minami, MD PhD, Toshihiro Miyamoto, MD PhD, Toru Sakura, PhD MD, Hiroatsu Iida, MD PhD, Yuqi Chen, PhD, Hitoshi Kiyoi, MD PhD

Blood (2018) 132 (Supplement 1): 5167.

https://doi.org/10.1182/blood-2018-99-112584

Published: 2018

Journal Articles

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Delphine Rea, MD, Fabian Lang, MD, Dong-Wook Kim, MD PhD, Jorge E. Cortes, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Hironobu Minami, MD PhD, Massimo Breccia, MD, Daniel J. Deangelo, MD, Andreas Hochhaus, MD, Moshe Talpaz, MD, Yeow Tee Goh, MBBS,MD, Philipp le Coutre, MD, Michael W. Deininger, MD PhD, Gabriel Etienne, MD PhD, Manu Sondhi, MD PhD, Kaushal Mishra, PhD, Paola Aimone, MD, Janet Ng-Sikorski, PhD, Michael J. Mauro, MD

Blood (2018) 132 (Supplement 1): 792.

https://doi.org/10.1182/blood-2018-99-113609

Published: 2018

Journal Articles

An mTORC1/2 Kinase Inhibitor Remarkably Enhances the Cytotoxicity of Gemtuzumab Ozogamicin By Activating Lysosomal Function and Cell Cycle Promotion in AML Cells

Yimamu Maimaitili, PhD, Aki Inase, PhD, Hironobu Minami, MD PhD, Hiroshi Matsuoka, MD PhD

Blood (2017) 130 (Supplement 1): 1374.

https://doi.org/10.1182/blood.V130.Suppl_1.1374.1374

Published: 2017

Journal Articles

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Aaron T. Gerds, MDMS, Tetsuzo Tauchi, MD, Ellen K. Ritchie, MD, Michael W. Deininger, MD PhD, Catriona HM Jamieson, MD PhD, Ruben Mesa, MD FACP, Mark Lawrence Heaney, MD PhD, Norio Komatsu, MD PhD, Hironobu Minami, MD PhD, M. Naveed Shaik, PhD, Xiaoxi Zhang, PhD, Christine DiRienzo, PhD, Mirjana Zeremski, MD, Geoffrey Chan, MD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 258.

https://doi.org/10.1182/blood.V130.Suppl_1.258.258

Published: 2017

Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Blood (2016) 128 (22): 625.

https://doi.org/10.1182/blood.V128.22.625.625

Published: 2016

Journal Articles

Biomarker and Gene Profiling Analyses in Acute Myeloid Leukemia during Treatment with Hedgehog Signaling Inhibitor

Seiji Kakiuchi, MD, Yosuke Minami, MD PhD, Nobuaki Fukushima, MD, Hiroshi Matsuoka, MD PhD, Tomoki Naoe, MD PhD, Hironobu Minami, MD D.MDSci.

Blood (2015) 126 (23): 1263.

https://doi.org/10.1182/blood.V126.23.1263.1263

Published: 2015

Journal Articles

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Oliver G. Ottmann, MD, Giuliana Alimena, Daniel J. DeAngelo, MD PhD, Yeow-Tee Goh, MBBS, MMed, Michael C. Heinrich, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Francois-Xavier Mahon, MD PhD Professor, Michael J. Mauro, MD, Hironobu Minami, MD D.MDSci., Marie Huong Nguyen, MD, Delphine Rea, Juan Luis Steegmann, MD, Arkendu Chatterjee, Varsha Iyer, Noelia Martinez, Gary J. Vanasse, MD, Kim Dong-Wook, MD PhD

Blood (2015) 126 (23): 138.

https://doi.org/10.1182/blood.V126.23.138.138

Published: 2015

Journal Articles

Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study

Blood (2014) 124 (21): 4131.

https://doi.org/10.1182/blood.V124.21.4131.4131

Published: 2014

Journal Articles

Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Bortezomib (B) in Patients (pts) with Relapsed Multiple Myeloma (MM): A Phase I/II Study in Japan.

Kensei Tobinai, MD, Takashi Watanabe, MD, Yoshiaki Ogawa, MD, Michinori Ogura, MD, Yasuo Morishima, MD, Hironobu Minami, MD, Kuniaki Itoh, MD, Tomomitsu Hotta, MD

Blood (2006) 108 (11): 5106.

https://doi.org/10.1182/blood.V108.11.5106.5106

Published: 2006

NARROW

Preclinical Evaluation of the Efficacy of Human Sirpα Antibodies for B-Cell Lymphoma Immunotherapy in Humanized Mouse Models

Routinely Calculable Biomarkers Are Associated with the Development of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation

Global Longitudinal Strain Is Superior to Ejection Fraction for Long-Term Follow-up after Allogeneic Hematopoietic Stem Cell Transplantation

Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

An mTORC1/2 Kinase Inhibitor Remarkably Enhances the Cytotoxicity of Gemtuzumab Ozogamicin By Activating Lysosomal Function and Cell Cycle Promotion in AML Cells

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Biomarker and Gene Profiling Analyses in Acute Myeloid Leukemia during Treatment with Hedgehog Signaling Inhibitor

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study

Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Bortezomib (B) in Patients (pts) with Relapsed Multiple Myeloma (MM): A Phase I/II Study in Japan.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only